Understanding how Parkin protein fights cancer
Parkin tumor suppression
This work explores how a protein called Parkin acts as a natural defense against cancer by affecting tumor growth and the body's immune response.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11161497 on NIH RePORTER |
What this research studies
Our bodies have natural defenses against cancer, and this project focuses on a protein called Parkin, which we've found acts as a tumor suppressor. Parkin works in two ways: it can directly slow down cancer cell movement and metabolism, and it can also help reprogram the immune system to better fight tumors. We believe Parkin helps activate immune cells, specifically CD8+ T cells, to infiltrate tumors and reduce other cells that suppress the immune response. Because Parkin is often silenced in human cancers, understanding its role could lead to new ways to boost the body's own defenses against many types of cancer.
Who could benefit from this research
Good fit: This foundational research is not directly recruiting patients but aims to benefit individuals with various types of cancer in the future.
Not a fit: Patients seeking immediate treatment options would not directly benefit from this basic science research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for cancer treatment by targeting the Parkin protein to enhance the body's natural ability to fight tumors.
How similar studies have performed: While the specific dual-mode tumor suppression mechanism of Parkin is a novel discovery, other studies have shown success in targeting immune pathways and cellular metabolism to fight cancer.
Where this research is happening
Philadelphia, United States
- Wistar Institute — Philadelphia, United States (Active)
Researchers
- Principal investigator: Altieri, Dario C — Wistar Institute
- Study coordinator: Altieri, Dario C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.